# A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

Source: https://onco.cc/trials/nct07054567/  
OnCo record `nct07054567` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Izalontamab brengitecan, Pembrolizumab, Bevacizumab in cervical cancer and endometrial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer is a phase 2 interventional study registered as NCT07054567 by Sichuan Baili Pharmaceutical Co., Ltd., with 96 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-05. Interventions recorded: BL-B01D1, Pembrolizumab, Bevacizumab. Conditions listed: Cervical Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07054567
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 + Pembrolizumab Dual Therapy With or Without Bevacizumab (BL-B01D1 + Pembrolizumab ± Bevacizumab) in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 96

## Sources

- ClinicalTrials.gov NCT07054567: https://clinicaltrials.gov/study/NCT07054567

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07054567.json